Cue Biopharma announced positive clinical updates for CUE-101, its lead drug candidate for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) driven by HPV16. The Phase 1 trial demonstrated a 50% overall response rate (ORR) in patients with a combined positive score (CPS) of 1 or greater, including a 50% ORR in the low CPS subgroup (1-19). Furthermore, the trial showed promising survival metrics, with a 12-month overall survival of 88% and a median overall survival of 32 months.
These results are particularly encouraging given the historical data from the KEYNOTE-048 trial, which showed a lower ORR of 19% and shorter survival metrics (12-month OS of 57% and mOS of 12.3 months) for pembrolizumab alone. The improved outcomes observed with CUE-101, especially in patients with low CPS, suggest its potential to address an unmet need for more effective therapies in this patient population. The observed complete response in a patient with multiple tumors, after a period of stable disease, further highlights the potential of CUE-101 to induce durable responses and even disease eradication. This extended response duration emphasizes the importance of continued monitoring in immunotherapy trials, as clinical activity may manifest differently compared to traditional treatments.
The data underscore the potential of CUE-101’s mechanism of action, which involves activating and expanding HPV16 tumor-specific T cells through a dual-signal approach. This innovative approach is designed to enhance the body’s natural immune response against HPV-driven cancers with improved selectivity. The reported 50% ORR in patients with low PD-L1 expression (CPS 1-19) is noteworthy, as these patients often have limited treatment options and poorer prognoses. The significant improvement in survival metrics, including the reduction in the risk of death compared to historical data, further supports the potential of CUE-101 to improve patient outcomes.
The maturing data for CUE-101 strengthens the case for its potential to become a new standard of care in HPV-positive HNSCC. This positive development also validates Cue Biopharma’s Immuno-STAT platform, suggesting its broader applicability in developing targeted immunotherapies for other cancers and autoimmune diseases. Further research and clinical trials will be essential to confirm these findings and explore the full potential of CUE-101 and the Immuno-STAT platform.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
